Trial
NCT03289039
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Puma Biotechnology, Inc.
Condition
Breast Cancer
Intervention
Neratinib
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-22